NCT04924075 2026-02-24
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2 Recruiting
Clinical Trials
3 trialsNCT04195750 2025-04-29
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03401788 2024-12-03
MK-6482-004
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Active not recruiting